Avasimibe (Synonyms: CI-1011; PD-148515)

Name: Avasimibe
Brand: MedChemExpress
SKU: HY-13215
Rating: 5.0 (17 reviews)

製品番号: HY-13215 純度: 99.77%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Avasimibe (CI-1011; PD-148515) is an orally active acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT)) inhibitor with IC₅₀s of 24 and 9.2 µM for ACAT1 and ACAT2, respectively. Avasimibe can be used for the research of prostate cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 166518-60-1

容量	価格（税別）	在庫状況	数量

>無料サンプル (0.1 - 0.2 mg)		今すぐ申し込む
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 39	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 39	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$35	在庫あり	Estimated Time of Arrival: December 31
10 mg	$55	在庫あり	Estimated Time of Arrival: December 31
25 mg	$120	在庫あり	Estimated Time of Arrival: December 31
50 mg	$198	在庫あり	Estimated Time of Arrival: December 31
100 mg	$352	在庫あり	Estimated Time of Arrival: December 31
200 mg	$572	在庫あり	Estimated Time of Arrival: December 31
500 mg		お問い合わせ
1 g		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 17 publication(s) in Google Scholar

Other Forms of Avasimibe:

Avasimibe (Standard) お問い合わせ

顧客検証

Cell Imaging/Staining

RT-PCR

Cell Proliferation/Viability Assay

In Vivo Efficacy Study

Cell Migration/Invasion Assay

: Avasimibe purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Dec 19. [Abstract]; Avasimibe (20 μM; 24 h). Western blot analysis of the expression levels of ACAT1 and IDH2-K272la in CMECs treated with the ACAT1 inhibitor Avasimibe under NOD and HOD stimulation.

: Avasimibe purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Dec 19. [Abstract]; Avasimibe (20 μM; 24 h). Coimmunoprecipitation experiment assessing the binding capacity of Cav1 with IDH2 and eNOS in CMECs treated with the ACAT1 inhibitor Avasimibe under NOD and HOD stimulation.

: Avasimibe purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Dec 19. [Abstract]; Avasimibe (20 μM; 24 h). Evaluation of tube formation, EdU proliferation, and NO production capabilities of CMECs treated with the ACAT1 inhibitor Avasimibe under HOD stimulation.

: Avasimibe purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Oct;130:110508. [Abstract]; Avasimibe (7.5 μM; 0-72 h). Inhibitory effects of Avasimibe on cell viability of T98 G and LN229 at different times.

: Avasimibe purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Oct;130:110508. [Abstract]; qRT-PCR data showing the expression of linc00339 in T98 G or LN229 cells treated with linc00339 plasmid, Avasimibe (7.5 μM for 48 h) alone or in combination with linc00339 plasmids.

: Avasimibe purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Oct;130:110508. [Abstract]; Colony formation assays showing the proliferation capacity of T98 G or LN229 cells treated with linc00339 plasmid, Avasimibe (7.5 μM for 48 h) alone or in combination with linc00339 plasmids.

: Avasimibe purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Oct;130:110508. [Abstract]; Avasimibe (7.5 μM for 48 h). LN229 cells treated with Avasimibe or combined with linc00339 plasmid were subcutaneously injected into the nude mice. Tumour formation in nude mice.

: Avasimibe purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Oct;130:110508. [Abstract]; Transwell assays showing the invasion capacity of T98 G or LN229 cells treated with linc00339 plasmid, Avasimibe (7.5 μM for 48 h) alone or in combination with linc00339 plasmids.

Acyltransferase アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

ACAT1 ACAT2 MGAT2 ACAT DGAT1 DGAT2

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Avasimibe (CI-1011; PD-148515) is an orally active acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT)) inhibitor with IC₅₀s of 24 and 9.2 µM for ACAT1 and ACAT2, respectively^[1]. Avasimibe can be used for the research of prostate cancer^[2].

IC₅₀ & Target^[1]

ACAT1

24 μM (IC₅₀)

ACAT2

9.2 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	CC₅₀	13.71 3 Compound: AVASIMIBE	Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay	10.21203/rs.3.rs-23951/v1
Caco-2	CC₅₀	13.71 3 Compound: AVASIMIBE	Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay	10.21203/rs.3.rs-23951/v1
Caco-2	CC₅₀	13.71 3 Compound: AVASIMIBE	Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay	10.21203/rs.3.rs-23951/v1
Caco-2	IC₅₀	3.93 3 Compound: AVASIMIBE	Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging	10.21203/rs.3.rs-23951/v1
Caco-2	IC₅₀	3.93 3 Compound: AVASIMIBE	Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging	10.21203/rs.3.rs-23951/v1
Caco-2	IC₅₀	3.93 3 Compound: AVASIMIBE	Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging	10.21203/rs.3.rs-23951/v1
HepG2	IC₅₀	479 1 Compound: avasimibe	Inhibition of ACAT in human HepG2 cells Inhibition of ACAT in human HepG2 cells	[PMID: 19167888]
THP-1	IC₅₀	1.5 3 Compound: avasimibe	Inhibition of ACAT-mediated esterified cholesterol accumulation in human THP1 cells exposed to acetyl-LDL during differentiation assessed as effect on foam cell formation Inhibition of ACAT-mediated esterified cholesterol accumulation in human THP1 cells exposed to acetyl-LDL during differentiation assessed as effect on foam cell formation	[PMID: 18620381]
HepG2	IC₅₀	479 1 Compound: avasimibe	Inhibition of ACAT in human HepG2 cells Inhibition of ACAT in human HepG2 cells	[PMID: 19167888]
THP-1	IC₅₀	1.5 3 Compound: avasimibe	Inhibition of ACAT-mediated esterified cholesterol accumulation in human THP1 cells exposed to acetyl-LDL during differentiation assessed as effect on foam cell formation Inhibition of ACAT-mediated esterified cholesterol accumulation in human THP1 cells exposed to acetyl-LDL during differentiation assessed as effect on foam cell formation	[PMID: 18620381]

体外実験

Avasimibe (0, 0.25, 5, 10, 20, 40 and 80 μM; for 1, 2, and 3 days) reduces proliferation in the prostate cancer (PCa) cells^[2].
Avasimibe (10 and 20 μM; 48 h) reduces the expression of β-catenin, Vimentin, N-cadherin, Snail and MMP9, which are tightly associated with epithelial-mesenchymal transition (EMT)^[2].
Avasimibe (10 and 20 μM) trigger cell cycle arrest via the E2F-1 signalling pathway in prostate cancer. Avasimibe induces G1 phase cell cycle arrest of PCa cells^[2].
Avasimibe (10 and 20 μM) inhibits the metastasis of PCa cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	PCa cells (PC-3 and DU 145)
Concentration:	0, 0.25, 5, 10, 20, 40 and 80 µM
Incubation Time:	1, 2, and 3 days
Result:	Dose dependently inhibited PC-3 and DU 145 cell viability.

Western Blot Analysis^[2]

Cell Line:	PCa cells (PC-3 and DU 145)
Concentration:	10 and 20 µM
Incubation Time:	48 hours
Result:	Reduced protein levels of EMT-related proteins (β-catenin, Vimentin, N-cadherin, Snail, MMP9 and E-cadherin).

Cell Cycle Analysis^[2]

Cell Line:	PCa cells (PC-3 and DU 145)
Concentration:	10 and 20 µM
Incubation Time:	48 hours
Result:	Induced G1 phase cycle arrest and altered the G1 phase-related protein levels in PCa cells.

体内実験

Avasimibe (30 mg/kg, intraperitoneally injected on alternate days for 7 weeks) suppresses PCa cell growth and metastasis in vivo. Avasimibe has good biocompatibility and low toxicity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SPF male mice (BALB/c-nude, 4 weeks old) bearing PCa cells^[2]
Dosage:	30 mg/kg
Administration:	Intraperitoneally injected for 7 weeks
Result:	Reduced tumour volume compared with that of the control group. Inhibited PCa growth and migration in vivo.

分子量

501.72

分子式

C₂₉H₄₃NO₄S

CAS 番号

166518-60-1

Appearance

Solid

Color

White to off-white

SMILES

O=C(NS(=O)(OC1=C(C(C)C)C=CC=C1C(C)C)=O)CC2=C(C(C)C)C=C(C(C)C)C=C2C(C)C

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (199.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9931 mL	9.9657 mL	19.9314 mL
5 mM	0.3986 mL	1.9931 mL	3.9863 mL
10 mM	0.1993 mL	0.9966 mL	1.9931 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 7.5 mg/mL (14.95 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 7.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 7.5 mg/mL (14.95 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 7.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: 7.5 mg/mL (14.95 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 7.5 mg/mL. If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.85%

Select Batch:

データシート (279 KB) SDS (393 KB)

COA (249 KB) LCMS (89 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Taichi Ohshiro,et al. Pyripyropene A, an acyl-coenzyme A:cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia. Arterioscler Thromb Vasc Biol. 2011 May;31(5):1108-15. [Content Brief]

[2]. Kangping Xiong, et al. The cholesterol esterification inhibitor avasimibe suppresses tumour proliferation and metastasis via the E2F-1 signalling pathway in prostate cancer.Cancer Cell Int. 2021 Aug 30;21(1):461. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9931 mL	9.9657 mL	19.9314 mL	49.8286 mL
	5 mM	0.3986 mL	1.9931 mL	3.9863 mL	9.9657 mL
	10 mM	0.1993 mL	0.9966 mL	1.9931 mL	4.9829 mL
	15 mM	0.1329 mL	0.6644 mL	1.3288 mL	3.3219 mL
	20 mM	0.0997 mL	0.4983 mL	0.9966 mL	2.4914 mL
	25 mM	0.0797 mL	0.3986 mL	0.7973 mL	1.9931 mL
	30 mM	0.0664 mL	0.3322 mL	0.6644 mL	1.6610 mL
	40 mM	0.0498 mL	0.2491 mL	0.4983 mL	1.2457 mL
	50 mM	0.0399 mL	0.1993 mL	0.3986 mL	0.9966 mL
	60 mM	0.0332 mL	0.1661 mL	0.3322 mL	0.8305 mL
	80 mM	0.0249 mL	0.1246 mL	0.2491 mL	0.6229 mL
	100 mM	0.0199 mL	0.0997 mL	0.1993 mL	0.4983 mL

Avasimibe Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

最近チェックした製品:

製品名

カスタマ需要量 *

お名前 *

タイトル

メールアドレス *

電話番号 *

デパートメント

組纖名 *

市区町村

都道府県

国或いは地域 *

必ず会社名を記載ください。個人への返信は行いません。

備考

製品名

Lot #

お名前 *

メールアドレス *

電話番号 *

部門 *

組纖名 *

国或いは地域 *

備考

Avasimibe (Synonyms: CI-1011; PD-148515)

カスタマーレビュー

Other Forms of Avasimibe:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Acyltransferase アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Avasimibe Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Avasimibe (Synonyms: CI-1011; PD-148515)

カスタマーレビュー

Other Forms of Avasimibe:

Avasimibe 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Acyltransferase アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Avasimibe 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Avasimibe Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report